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Background: Tiotropium þ olodaterol improves lung function and symptoms compared to mono-
therapies in chronic obstructive pulmonary disease (COPD). The OTEMTO 1 and 2 studies investigated
the effects of tiotropium þ olodaterol on lung function and health-related quality of life compared to
placebo in patients with moderate to severe COPD.
Methods: In these two replicate, double-blind, parallel-group, placebo-controlled trials, patients were
randomised to receive tiotropium þ olodaterol 5/5 mg, 2.5/5 mg, tiotropium 5 mg or placebo for 12 weeks,
via the Respimat® inhaler. Primary end points were St George's Respiratory Questionnaire (SGRQ) total
score, forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0e3) response and
trough FEV1 response.
Results: In OTEMTO 1 and 2, tiotropium þ olodaterol 5/5 mg improved SGRQ total score by 4.89 (95%
conﬁdence interval [CI] 6.90, 2.88) and 4.56 (95% CI 6.50, 2.63) units versus placebo (both
p < 0.0001), and 2.49 (95% CI 4.47, 0.51; p < 0.05) and 1.72 (95% CI 3.63, 0.19) units versus tiotropium
5 mg. Tiotropium þ olodaterol 2.5/5 mg signiﬁcantly improved SGRQ score compared to placebo. Both
doses signiﬁcantly improved FEV1 AUC0e3 response compared to placebo and tiotropium 5 mg.
Tiotropium þ olodaterol 5/5 and 2.5/5 mg also signiﬁcantly improved trough FEV1 response compared to
placebo (both studies) and separated from tiotropium 5 mg in OTEMTO 2. Adverse-event incidence was
similar between treatment groups.
Conclusion: Tiotropium þ olodaterol improved lung function and quality of life compared to placebo and
tiotropium 5 mg.
Trial registration: ClinicalTrials.gov: NCT01964352 and NCT02006732.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).der the curve from 0 to 3 h;
forced expiratory volume in
ng Disease; FVC, forced vital
cting muscarinic antagonist;
RQ, St George's Respiratory
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Ltd. This is an open access article u1. Introduction
Tiotropium was the ﬁrst once-daily long-acting muscarinic
antagonist (LAMA) to be approved for the treatment of chronic
obstructive pulmonary disease (COPD) and has now been devel-
oped in a ﬁxed-dose combination with the once-daily long-acting
b2-agonist (LABA) olodaterol. Olodaterol is approved for the treat-
ment of COPD and has an early onset of action and a 24-h effect on
lung function [1e4]. The efﬁcacy and tolerability of olodaterol was
demonstrated in a large Phase III programme [1e5]. Combinationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the Global initiative for chronic Obstructive Lung Disease (GOLD)
report [6].
Data from the tiotropium þ olodaterol Phase III studies have
demonstrated signiﬁcant improvements in lung function to a
greater extent than tiotropium and olodaterol monocomponents,
with no additional safety concerns [7,8]. The TONADO studies were
two large replicate Phase III trials that demonstrated improvements
in lung function and St George's Respiratory Questionnaire (SGRQ)
total score over 52 weeks with tiotropium þ olodaterol versus the
monocomponents in patients with moderate to very severe COPD.
In the TONADO studies, it was not possible to include a placebo
arm due to the 52-week duration and the inclusion of patients with
very severe COPD. The effects of bronchodilator therapies on
patient-reported outcomes are best investigated in placebo-
controlled studies in order to understand whether the minimum
clinically important difference (MCID) compared to placebo is
achieved. The novelty of the OTEMTO studies was the inclusion of a
placebo arm; the study design involved a shorter duration and the
exclusion of patients with GOLD 4 disease in order to allow this. In
addition, both the tiotropium þ olodaterol 2.5/5 mg and 5/5 mg
doses were included to investigate differences in effect size be-
tween the two doses.
The objective of the OTEMTO studies was to evaluate the effect of
tiotropium þ olodaterol on lung-function improvement and health-
related quality of life after 12 weeks of treatment compared to pla-
cebo and tiotropium 5 mg in patients with moderate to severe COPD.
2. Methods
2.1. Study design
These were two replicate, multinational, double-blind, parallel-
group, placebo-controlled studies (OTEMTO 1, 1237.25,
NCT01964352; OTEMTO 2, 1237.26, NCT02006732) in which pa-
tients were randomised to receive one of four treatments once daily
for 12 weeks, all delivered via the Respimat® inhaler: placebo,
tiotropium 5 mg, tiotropium þ olodaterol 2.5/5 mg and
tiotropium þ olodaterol 5/5 mg (Fig. 1).
After completing an initial screening visit, patients entered a 2-
week screening period prior to randomisation. A follow-up visit
took place ~3 weeks after last dose of study medication.
2.2. Patients
Patients aged 40 years with moderate to severe COPD (GOLDFig. 1. OTEMTO study design. R, randomisation.2e3; post-bronchodilator forced expiratory volume in 1 s [FEV1]
30% and <80% of predicted normal), FEV1/forced vital capacity
(FVC) <70% predicted and a smoking history of >10 pack-years
were included. Patients were excluded if they had a history of
asthma, another signiﬁcant disease, COPD exacerbation or symp-
toms of lower respiratory tract infection within the previous 3
months, unstable or life-threatening cardiac arrhythmia, hospital-
isation for heart failure within the past year, a history of myocardial
infarction within 1 year of screening or a history of life-threatening
pulmonary obstruction.
Patients were allowed to continue their inhaled corticosteroid
therapy (if they were on a stable dose for 6 weeks prior to
screening). LAMAs or LABAs other than study medication were
prohibited during the screening or treatment periods, and short-
acting muscarinic antagonists were permitted only during the
screening period. Open-label salbutamol was provided as rescue
medication for use throughout the study.
2.3. Study outcomes
The three primary end points, measured at 12 weeks, were
SGRQ total score, FEV1 area under the curve from 0 to 3 h (AUC0e3)
response (change from baseline) and trough FEV1 response. Trough
FEV1 was deﬁned as the mean of the FEV1 values at 23 h post-dose
and 23 h 50 min post-dose.
The secondary end points were Mahler Transition Dyspnoea
Index (TDI) focal score and, trough FVC and FVC AUC0e3 responses.
All adverse events (AEs) and serious AEs were reported, vital signs
were monitored and 12-lead electrocardiogram recordings were
taken for all patients at screening and at Week 12, with any ab-
normalities reported as AEs.
2.4. Assessments
Pulmonary function testing was performed according to Amer-
ican Thoracic Society/European Respiratory Society guidelines [9]
and tests were performed in triplicate, with the highest FEV1 and
FVC being reported. Pulmonary function tests were performed at
1 h pre-dose, 10 min pre-dose, 5, 15 and 30 min post-dose and 1, 2
and 3 h post-dose at baseline and Week 12, and at 10 min pre-dose
only after 2 and 6 weeks of treatment. The ﬁnal trough FEV1
measurement was taken the day after theWeek 12 visit (at 23 h and
23 h 50 min post-dose). Further information about the spirometry
methodology is provided in the Supplementary material.
Patients completed the SGRQ at baseline and at Weeks 6 and 12,
before any other assessments at that visit. The questionnaire con-
sists of 16 questions about patients' recollections of their symptoms
over the past month (Questions 1e8) and their current state,
including activity levels and impact on functioning (Questions
9e16). Patients completed the questionnaire in the clinic.
The Mahler Baseline Dyspnoea Index was administered at
baseline and used as the baseline value for analyses of TDI score.
The TDI was administered at Week 6 and Week 12 and consists of
an interview to measure the level and extent of activities patients
can perform before feeling breathless, relative to their baseline
performance. The interviews were conducted by trained clinic staff.
2.5. Statistical analysis
The pre-speciﬁed analyses of the study were designed to test
tiotropium þ olodaterol versus placebo for all of the primary end
points; the hypothesis testing strategy is presented in
Supplementary Fig. S1. Assuming standard deviations of 0.226 L for
FEV1 AUC0e3 and 0.225 L for trough FEV1, and a two-sided alpha of
0.05, a sample size of 200 patients per group per trial was required
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AUC0e3 and trough FEV1. Assuming a standard deviation of 14 units
for SGRQ score, 400 patients per group were required in the com-
bined data set for OTEMTO 1 and 2 to provide 90% power to detect a
difference of 3.2 units in SGRQ total score and 98% power to detect a
difference of 4 units in SGRQ total score.
Two replicate studies were conducted to demonstrate duplica-
tion of the data, with each individual study powered to detect a
change in the primary end points. In addition, the data from the
two studies were combined in the pre-speciﬁed analysis of the
SGRQ total score, providing greater power for this end point.
The primary analyses were intent-to-treat analyses, performed
on the full analysis set, deﬁned as all patients who received at least
one dose of study medication and had baseline and at least one
post-baseline measurement for any of the primary end points.
Changes from baseline in FEV1 AUC0e3 and trough FEV1 were
analysed using a restricted maximum likelihood-based mixed ef-
fects model repeated measures, including the ﬁxed categorical ef-
fects of treatment, test day and treatment-by-test-day interaction,
as well as the continuous ﬁxed covariates of baseline and baseline-
by-test-day interaction.
A responder analysis on the SGRQ total score was performed,
with patients classed as responders if their improvement in SGRQ
total score was 4.0 units, and a logistical regression, which
included the ﬁxed categorical effect of treatment and baseline as
ﬁxed continuous covariate, was used to calculate the odds ratio of
responder between treatment groups.
3. Results
3.1. Patient disposition and baseline characteristics
In OTEMTO 1, 1054 patients were enrolled, 814 patients were
randomised and 812 treated, with 93.7% of patients completing the
trial (Fig. 2a).
In OTEMTO 2, of the 1107 patients enrolled, 809 were rando-
mised and treated, and 94.4% of patients completed the trial
(Fig. 2b). In both studies, discontinuation rates were highest in the
placebo arm (Fig. 2). Patient demographics and baseline charac-
teristics were similar between groups, and between trials (Table 1).
3.2. Primary end points
3.2.1. SGRQ
Tiotropium þ olodaterol 5/5 mg improved SGRQ total score at 12
weeks by 4.89 units and 4.56 units versus placebo (p < 0.0001) in
OTEMTO 1 and 2, respectively (Fig. 3); the improvement compared
to tiotropium 5 mg was 2.49 units (p ¼ 0.0136) and 1.72 units
(p ¼ 0.0780), respectively (Table 2). Tiotropium þ olodaterol 2.5/
5 mg also signiﬁcantly improved SGRQ score compared to placebo in
both studies (by 4.12 and 3.67 units) (Fig. 3), though differences
compared to tiotropium 5 mg were not signiﬁcant (Table 2). In
addition, there was a numerically greater improvement in SGRQ
with tiotropium þ olodaterol 5/5 mg compared to
tiotropium þ olodaterol 2.5/5 mg. Data from the combined analysis
of the two studies are presented in Supplementary Table S1.
3.2.2. FEV1 AUC0e3
Both tiotropium þ olodaterol dose strengths signiﬁcantly
improved FEV1 AUC0e3 response after 12 weeks compared to pla-
cebo (0.331 L and 0.299 L with tiotropium þ olodaterol 5/5 mg, and
0.300 L and 0.284 L with tiotropium þ olodaterol 2.5/5 mg, in
OTEMTO 1 and 2, respectively; all comparisons p < 0.0001). There
were no signiﬁcant differences between tiotropium þ olodaterol
doses. Signiﬁcant differences versus tiotropium 5 mg were alsoobserved with both doses (all comparisons p < 0.0001) (Fig. 4;
Supplementary Table S2).
3.2.3. Trough FEV1
Tiotropium þ olodaterol 5/5 mg signiﬁcantly improved trough
FEV1 response after 12 weeks by 0.162 L and 0.166 L compared to
placebo (p < 0.0001) in OTEMTO 1 and 2 (Fig. 4; Supplementary
Table S2).
Tiotropium þ olodaterol 2.5/5 mg signiﬁcantly improved trough
FEV1 response compared to placebo in both studies; the effects of
both doses were similar. Both tiotropium þ olodaterol doses also
had a greater effect than tiotropium 5 mg in OTEMTO 2 (5/5 mg,
0.039 L, p ¼ 0.0395; 2.5/5 mg, 0.042 L, p ¼ 0.0269) but not in
OTEMTO 1 (Fig. 4; Supplementary Table S2).
3.3. Secondary end points
3.3.1. TDI focal score
Tiotropium þ olodaterol 5/5 mg signiﬁcantly improved TDI focal
score at 12 weeks compared to placebo (2.05 and 1.20 units,
p < 0.0001) and tiotropium 5 mg (0.61 and 0.58 units, p < 0.05)
(Fig. 5; Supplementary Table S3). Tiotropium þ olodaterol 2.5/5 mg
improved TDI focal score compared to placebo in both studies, and
compared to tiotropium 5 mg in OTEMTO 2 only (Fig. 5;
Supplementary Table S3).
3.3.2. FVC AUC0e3 and trough FVC
Both tiotropium þ olodaterol doses increased FVC AUC0e3
versus placebo and tiotropium 5 mg in both studies. Both dose
strengths also increased trough FVC compared to placebo but only
tiotropium þ olodaterol 2.5/5 mg in OTEMTO 2 showed a signiﬁcant
difference from tiotropium 5 mg in trough FVC (Fig. 6;
Supplementary Table S4).
3.4. Further end points
3.4.1. SGRQ responder analysis
Tiotropium þ olodaterol 5/5 mg increased the percentage of
patients classed as SGRQ responders (improvement from baseline
of4.0 units) at 12weeks compared to placebo and tiotropium 5 mg
(Supplementary Table S5). In OTEMTO 1, the responder rates were
31.2%, 41.7%, 46.2% and 53.1% with placebo, tiotropium 5 mg,
tiotropium þ olodaterol 2.5/5 mg and 5/5 mg, respectively, with
tiotropiumþ olodaterol 5/5 mg and 2.5/5 mg signiﬁcantly separating
from placebo (odds ratios 2.495 [p < 0.0001], 1.898 [p ¼ 0.0026],
respectively) and tiotropium þ olodaterol 5/5 mg separating from
tiotropium 5 mg (odds ratio 1.583; p ¼ 0.0249). In OTEMTO 2,
responder rates were 32.6%, 41.1%, 47.2% and 51.8% with placebo,
tiotropium 5 mg, tiotropium þ olodaterol 2.5/5 mg and 5/5 mg,
respectively. Tiotropium þ olodaterol 5/5 mg and 2.5/5 mg signiﬁ-
cantly separated from placebo (odds ratios 2.219 [p¼ 0.0002],1.846
[p ¼ 0.0040]) and tiotropium þ olodaterol 5/5 mg separated from
tiotropium 5 mg (odds ratio 1.536; p ¼ 0.0359) (Supplementary
Table S5).
3.5. Safety end points
IncidenceofAEswasbroadlysimilaracross treatmentgroups,with
a higher incidence of AEs leading to discontinuation in the placebo
groups compared to the treatment groups in both studies
(SupplementaryTableS6). Incidences ofAEs in the “cardiacdisorders”
Systems Organ Class were 0.0e3.0% with tiotropium þ olodaterol,
1.0e1.5% with tiotropium 5 mg and 2.0e3.9% with placebo. Incidence
of vascular disorders is shown in Supplementary Table S6. No safety
concerns were raised from vital signs.
Fig. 2. Patient disposition in (a) OTEMTO 1 and (b) OTEMTO 2. T, tiotropium; O, olodaterol; AE, adverse event.
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OTEMTO 1 and 2 demonstrated that tiotropium þ olodaterol 5/
5 mg improves lung function and health-related quality of life after
12 weeks compared to placebo and tiotropium 5 mg.
Tiotropium þ olodaterol 5/5 mg improved SGRQ total score by 4.89
and 4.56 units compared to placebo in OTEMTO 1 and 2, respec-
tively, which is greater than the threshold of 4 units considered to
be clinically meaningful [10]. This suggests that the signiﬁcant
improvements in lung function demonstrated here using
tiotropiumþ olodaterol 5/5 mg have clinicallymeaningful effects on
patients' lives.There has been much debate regarding the clinical beneﬁt of
anticholinergic þ b-adrenergic combination therapies in COPD, as
improvements in lung functionwith these combinations have often
been associated with only small or inconsistent improvements in
patient-reported outcomes compared to monotherapies [11,12].
Here we show that tiotropium þ olodaterol 5/5 mg consistently
achieved improvements in mean SGRQ total score greater than the
MCID threshold while tiotropium monotherapy did not, and there
was an ~1.5-fold increase in the odds ratio of being an SGRQ
responder with tiotropium þ olodaterol 5/5 mg compared to tio-
tropium. Tiotropium þ olodaterol 2.5/5 mg did not achieve the
MCID in mean SGRQ score and had a lower responder rate than
Table 1
Patient demographics and baseline characteristics (treated set).
OTEMTO 1 OTEMTO 2
Placebo T 5 mg T þ O 2.5/5 mg T þ O 5/5 mg Placebo T 5 mg T þ O 2.5/5 mg T þ O 5/5 mg
Patients, n 204 (100.0) 203 (100.0) 202 (100.0) 203 (100.0) 202 (100.0) 203 (100.0) 202 (100.0) 202 (100.0)
Male, n (%) 127 (62.3) 124 (61.1) 116 (57.4) 114 (56.2) 117 (57.9) 130 (64.0) 126 (62.4) 133 (65.8)
Mean (SD) age, years 65.1 (8.3) 64.9 (8.2) 64.7 (8.2) 64.7 (8.9) 64.0 (8.3) 64.7 (8.4) 64.4 (8.6) 65.2 (8.5)
Smoking status, n (%)
Ex-smoker 116 (56.9) 105 (51.7) 104 (51.5) 92 (45.3) 107 (53.0) 112 (55.2) 112 (55.4) 110 (54.5)
Current smoker 88 (43.1) 98 (48.3) 98 (48.5) 111 (54.7) 95 (47.0) 91 (44.8) 90 (44.6) 92 (45.5)
Pre-bronchodilator
Mean (SD) FEV1, L 1.383 (0.527) 1.306 (0.458) 1.326 (0.505) 1.315 (0.491) 1.333 (0.493) 1.403 (0.511) 1.348 (0.478) 1.358 (0.467)
Mean (SD) FVC, L 2.906 (0.826) 2.775 (0.853) 2.797 (0.878) 2.802 (0.860) 2.757 (0.837) 2.805 (0.858) 2.740 (0.826) 2.807 (0.826)
Post-bronchodilatora
Mean (SD) FEV1, L 1.578 (0.539) 1.494 (0.471) 1.510 (0.521) 1.502 (0.502) 1.530 (0.527) 1.585 (0.514) 1.521 (0.474) 1.566 (0.482)
Mean (SD) FEV1 % predicted 56.3 (12.8) 54.7 (12.8) 55.5 (13.7) 54.9 (12.0) 54.3 (13.4) 55.9 (12.2) 54.5 (12.7) 54.8 (12.8)
Mean (SD) FVC, L 3.192 (0.860) 3.063 (0.881) 3.082 (0.924) 3.105 (0.891) 3.071 (0.898) 3.060 (0.874) 2.996 (0.845) 3.122 (0.887)
Mean (SD) FEV1/FVC, % 49.7 (10.9) 49.6 (10.5) 49.4 (10.1) 49.0 (10.3) 50.2 (10.5) 52.4 (10.7) 51.3 (10.0) 50.9 (10.0)
GOLD, n (%)b
1 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
2 140 (68.6) 127 (62.6) 132 (65.3) 130 (64.0) 122 (60.4) 137 (67.5) 129 (63.9) 125 (61.9)
3 63 (30.9) 73 (36.0) 69 (34.2) 73 (36.0) 79 (39.1) 66 (32.5) 70 (34.7) 77 (38.1)
4 1 (0.5) 2 (1.0) 1 (0.5) 0 (0.0) 1 (0.5) 0 (0.0) 3 (1.5) 0 (0.0)
Baseline pulmonary medication, n (%)
Any 156 (76.5) 160 (78.8) 161 (79.7) 162 (79.8) 156 (77.2) 158 (77.8) 145 (71.8) 142 (70.3)
ICS 71 (34.8) 77 (37.9) 78 (38.6) 85 (41.9) 71 (35.1) 71 (35.0) 83 (41.1) 72 (35.6)
LAMA 83 (40.7) 64 (31.5) 61 (30.2) 77 (37.9) 59 (29.2) 77 (37.9) 69 (34.2) 70 (34.7)
SAMA 13 (6.4) 18 (8.9) 21 (10.4) 20 (9.9) 16 (7.9) 15 (7.4) 12 (5.9) 9 (4.5)
LABA 78 (38.2) 78 (38.4) 80 (39.6) 73 (36.0) 76 (37.6) 81 (39.9) 81 (40.1) 82 (40.6)
SABA 101 (49.5) 112 (55.2) 107 (53.0) 100 (49.3) 107 (53.0) 109 (53.7) 89 (44.1) 93 (46.0)
SD, standard deviation; FEV1, forced expiratory volume in 1 s; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LAMA, long-acting
muscarinic antagonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting b2-agonist; SABA, short-acting b2-agonist.
a Post-bronchodilator results were obtained after 4 puffs of 100 mg salmeterol.
b Although the inclusion criteria only included patients with GOLD 2e3 COPD, 4 patients (0.5%) in each trial were classed as GOLD 4 and 1 (0.1%) in OTEMTO 1 as GOLD 1,
based on their entrance spirometry results.
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5 mg provided patients with COPD with a greater opportunity for a
clinically signiﬁcant improvement in health status compared to the
other active treatments in this study.
A relationship exists in COPD between improvements in FEV17
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Fig. 3. SGRQ total score difference from placebo in OTEMTO 1 and 2 after 12 weeks
(full analysis set). T, tiotropium; O, olodaterol; SE, standard error; SGRQ, St George's
Respiratory Questionnaire.and patient-reported outcomes, with greater bronchodilation
linked to greater symptomatic beneﬁt. However, the level of change
seen in patient-reported outcomes in several studies with
anticholinergic þ b-adrenergic combinations compared to mono-
therapies has not met the criteria for the MCID. Several potential
reasons may explain this, including lack of statistical power, as
patient-reported outcomes are often secondary end points and the
studies are not speciﬁcally powered for these end points. Further-
more, MCID values were established for comparison to placebo, so a
value of 4 units for SGRQ is probably not appropriate for deter-
mining the additional value when comparing two active treat-
ments. The OTEMTO studies were formally powered to detect
differences between tiotropium þ olodaterol and placebo for SGRQ
total score as a primary end point.
Similarly, other once-daily anticholinergic þ b-adrenergic
combinations have also demonstrated improvements in SGRQ total
score compared to placebo [13,14]; indacaterol þ glycopyrronium
improved SGRQ total score by 2.13 units compared to tiotropium
Handihaler 18 mg after 26 weeks, though it did not reach the 4-unit
threshold versus placebo [13,15]. A difference of 2.10 units between
umeclidinium þ vilanterol and tiotropium has also been observed
after 24 weeks [12], though in two other studies there was no
signiﬁcant difference versus tiotropium monotherapy [16]. The
magnitude of SGRQ difference between tiotropium þ olodaterol 5/
5 mg and tiotropiummonotherapy was larger in the pooled analysis
of the OTEMTO studies (2.10 units) than in the TONADO studies
(1.23 units) [7].
The improvement in health-related quality of life with
tiotropium þ olodaterol is further supported by the improvement
in breathlessness measured using TDI focal score:
tiotropium þ olodaterol 5/5 mg increased TDI focal score by 2.05
(OTEMTO 1) and 1.20 (OTEMTO 2) units compared to placebo,
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error; FEV1, forced expiratory volume in 1 s; AUC0e3, area under the curve from 0 to
3 h.
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Fig. 5. Mean difference from placebo in TDI score after 12 weeks (full analysis set). T,
tiotropium; O, olodaterol; SE, standard error; TDI, Transition Dyspnoea Index.
Table 2
SGRQ total score in OTEMTO 1 and 2 after 12 weeks (full analysis set).
Treatment SGRQ total score
Mean (SE) Mean (SE) difference 95% CI
OTEMTO 1
Common baseline mean 42.43 (0.62)
T þ O 5/5 mg 37.14 (0.71)
versus placebo 4.89 (1.02)*** 6.90, 2.88
versus T 5 mg 2.49 (1.01)* 4.47, 0.51
T þ O 2.5/5 mg 37.92 (0.71)
versus placebo 4.12 (1.02)*** 6.13, 2.11
versus T 5 mg 1.72 (1.01) 3.70, 0.26
T þ O 5/5 mg
versus T þ O 2.5/5 mg 0.77 (1.00) 2.74, 1.20
T 5 mg 39.64 (0.72)
versus placebo 2.40 (1.03)* 4.42, 0.38
Placebo 42.04 (0.74)
OTEMTO 2
Common baseline mean 42.70 (0.62)
T þ O 5/5 mg 38.01 (0.68)
versus placebo 4.56 (0.99)*** 6.50, 2.63
versus T 5 mg 1.72 (0.97) 3.63, 0.19
T þ O 2.5/5 mg 38.91 (0.69)
versus placebo 3.67 (0.99)** 5.61, 1.72
versus T 5 mg 0.82 (0.98) 2.74, 1.10
T þ O 5/5 mg
versus T þ O 2.5/5 mg 0.90 (0.97) 2.80, 1.01
T 5 mg 39.73 (0.69)
versus placebo 2.85 (0.99)* 4.80, 0.90
Placebo 42.58 (0.71)
*p < 0.05; **p < 0.001; ***p < 0.0001.
OTEMTO 1: placebo, n ¼ 186; T 5 mg, n ¼ 192; T þ O 2.5/5 mg, n ¼ 199; T þ O 5/5 mg,
n¼ 196; OTEMTO 2: placebo, n¼ 184; T 5 mg, n¼ 192; Tþ O 2.5/5 mg, n¼ 195; Tþ O
5/5 mg, n ¼ 197.
SGRQ, St George's Respiratory Questionnaire; SE, standard error; CI, conﬁdence
interval; T, tiotropium; O, olodaterol.
D. Singh et al. / Respiratory Medicine 109 (2015) 1312e1319 1317which is greater than the 1-unit threshold for clinically important
improvement [17]. Statistically signiﬁcant improvements
compared to tiotropium 5 mg were also observed, suggesting that
the beneﬁts of combined therapy on FEV1 in comparison to tio-
tropium 5 mg lead to incremental improvements in dyspnoea.
The improvement in FEV1 AUC0e3 observed with
tiotropiumþ olodaterol 5/5 mg in the OTEMTO studies is also in line
with the effect sizes observed versus tiotropium 5 mg in the
TONADO studies. Greater improvements in trough FEV1 versus
tiotropium 5 mg were reported in the TONADO trials and versus
tiotropium 5 mg and placebo in the VIVACITO study (improvement
of 0.207 L versus placebo) than the OTEMTO trials [7,8].
It is interesting to note that while there appeared to be only a
small difference in lung function between the two doses of
tiotropiumþ olodaterol, there was a separation in SGRQ score, with
only the 5/5 mg dose showing a statistically signiﬁcant improve-
ment in SGRQ total score versus tiotropiummonotherapy (OTEMTO
1 and combined analysis).
Beyond the lung-function effect, combination of tiotropium
with a LABA has been shown to improve respiratory muscle
strength [18], as well as reducing hyperinﬂation, leading to
improved physical performance [19]. Thus, given the improvement
in health-related quality of life with tiotropium þ olodaterol, it will
be interesting to investigate its effects on overall physical perfor-
mance. The data from the studies reported here, together with
others, suggest that FEV1 alone may not fully capture the impact of
a treatment on patients' lives, and patient-centred outcomes such
as the SGRQ may help to investigate this [15].
The incidence of AEs was similar between treatment groups,
with no increase in incidence with tiotropium þ olodaterol
compared to tiotropium alone or placebo. This was similar to the
TONADO studies, in which there was no increase in AEs withtiotropium þ olodaterol compared to tiotropium [7].
The discontinuation rate was higher in the placebo arm than in
the treatment arms in these studies, most likely accounted for by
the most severely ill patients dropping out of the studies. With
higher discontinuation in the placebo arm, we would have ex-
pected to see a positive placebo effect but in these studies this was
not the case, and the placebo arm remained relatively stable in
terms of lung function and SGRQ score.
Possible weaknesses of these studies are the short duration and
a lack of patients with GOLD 4 COPD but these aspects were
important as they allowed comparisons between
tiotropium þ olodaterol and placebo in SGRQ score and lung
function, which provided valuable data.
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Fig. 6. (a) Mean FVC AUC0e3 and (b) trough FVC response differences from placebo
after 12 weeks (full analysis set). T, tiotropium; O, olodaterol; SE, standard error; FVC,
forced vital capacity; AUC0e3, area under the curve from 0 to 3 h.
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The OTEMTO studies demonstrated improvements in lung
functionwith tiotropium þ olodaterol over placebo and tiotropium
5 mg that were translated into clinically signiﬁcant improvements in
symptoms and health-related quality of life.
Tiotropium þ olodaterol 5/5 mg demonstrated a greater effect on
SGRQ than tiotropium þ olodaterol 2.5/5 mg.Conﬂicts of interest
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